KEGG   DRUG: Efgartigimod alfa
Entry
D11876                      Drug                                   
Name
Efgartigimod alfa (USAN/INN);
Efgartigimod alfa (genetical recombination) (JAN);
Efgartigimod alfa-fcab;
Vyvgart (TN)
Product
VYVGART (argenx US)
Formula
C2310H3554N602O692S14
Exact mass
51247.7506
Mol weight
51279.464
Sequence
DKTHTCPPCP APELLGGPSV FLFPPKPKDT LYITREPEVT CVVVDVSHED PEVKFNWYVD
GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALKFHYTQKS LSLSPGK
(Disulfide bridge: 6-6', 9-9', 41-101, 147-205, 41'-101', 147'-205')
  Type
Peptide
Remark
Therapeutic category: 6399
ATC code: L04AA58
Product: D11876<JP/US>
Product (mixture): D12684<JP/US>
Efficacy
Autoimmune disease treatment
  Disease
Generalized myasthenia gravis (AChR antibody positive) [DS:H01594]
Comment
Treatment of IgG-driven autoimmune diseases
Target
FCGRT [HSA:2217] [KO:K24019]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA58 Efgartigimod alfa
      D11876  Efgartigimod alfa (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antimyasthenic Agents
  Efgartigimod Alfa
   D11876  Efgartigimod alfa (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D11876  Efgartigimod alfa (USAN/INN); Efgartigimod alfa (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Immune system
    FCGRT
     D11876  Efgartigimod alfa (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11876
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11876
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11876
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11876
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D11876
Other DBs
CAS: 1821402-21-4
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system